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Mammalian musculature is a very robust and dynamic tissue that goes through many
rounds of degeneration and regeneration in an individual’s lifetime. There is a biological
program that maintains muscle progenitor cells that, when activated, give rise to interme-
diate myoblast progeny that consequently differentiate into mature muscle cells. Recent
works have provided a picture of the role that microRNAs (miRNAs) play in maintaining
aspects of this program. Intriguingly, a subset of these miRNAs is de-regulated in mus-
cular dystrophies (MDs), a group of fatal inherited neuromuscular disorders that are often
associated with deﬁciencies in the Dystrophin (Dys) complex. Apparently, transcriptional
expression of many of the muscle speciﬁc genes and miRNAs is dependent on chromatin
state regulated by the Dys–Syn–nNOS pathway.This puts Dystrophin at the epicenter of a
highly regulated program of muscle gene expression in which miRNAs help to coordinate
networking between multiple phases of muscle maintenance, degeneration, and regener-
ation. Therefore, understanding the role of miRNAs in physiology of normal and diseased
muscle tissue could be useful for future applications in improving the MD therapies and
could open new clinical perspectives.
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FUNCTION OF THE DYSTROPHIN GLYCOPROTEIN COMPLEX
Muscular dystrophies (MDs) are a group of fatal inherited dis-
eases (∼30), associated with progressive muscle wasting caused by
musclemembrane fragility, abnormalmetabolic control, increased
oxidative and energetic stress and abnormal proliferation of satel-
lite cells (Campbell, 1995; Cohn and Campbell, 2000; Constantin
et al., 2006;Vercherat et al., 2009;Wallace and McNally, 2009). The
most prevalent and severe Duchenne MD (DMD) and the milder
Becker MD (BMD) both result from mutations in the Dystrophin
(Dys) gene. Dys, the largest gene in the human genome (1.2 Mb,
79 exons), encodes a structural cytoplasmic protein that is the key
component of the larger membrane-associated multiprotein dys-
trophin glycoprotein complex (DGC;Kunkel et al., 1986;Hoffman
et al., 1987). The DGC classically consists of dystrophin, dystro-
glycans α and β, sarcoglycans α, β, γ, and δ, sarcospan, and other
proteins, such as α-dystrobrevin, syntrophins α1, β1, β2, γ1, γ2,
calveolin-3, Growth factor receptor–bound protein-2 (Grb2), and
neuronal Nitric Oxide Synthase (nNOS) have been shown to be
associated with the DGC (Durbeej and Campbell, 2002).
The DGC has multiple roles in muscle: mechanical stabiliza-
tion of the muscle sarcolemma via anchoring the extracellular
matrix (ECM) to the cytoskeleton, signal transduction between
the internal and external environments of the muscle cell and
provides a scaffold responsible for the membrane localization of
signaling proteins (Ervasti and Sonnemann, 2008). The DGC, via
Syntrophin (Syn) anchors a variety of signaling molecules to their
functional sites at the membrane. For example, it localizes nNOS
at the sarcolemma consequently regulating intramuscular gener-
ation of nitric oxide (NO; Wehling et al., 2001). nNOS signaling
nitrosylates the histone deacetylases (HDACs) that regulate gene
transcription in muscle progenitor cells by controlling the activ-
ity of myogenic (MyoD, Myf5, myogenin, and MRF4) and MEF2
family proteins (McKinsey et al., 2000; Puri et al., 2001). Upon
myoblast differentiation,HDACs are displaced from the chromatin
that then becomes hyperacetylated leading to transcriptional acti-
vation. Since Dys deﬁciency leads to downregulation of nNOS
signaling (Brenman et al., 1995), it indirectly plays a role in con-
trol of the balance between acetylation anddeacetylation of muscle
differentiation genes and has an impact on the regenerative poten-
tial of muscle stem cells. It is not clear if the DGC is just a scaffold
for Syn–nNOS or, since it has been shown that the DGC is also
a signal-transducing module involved in cross talk between the
internal and external environments of the muscle cell (Moore and
Winder,2010), it can also actively control epigenetic characteristics
of muscle cells via the nNOS signaling pathway.
MUSCLE MAINTENANCE AND REGENERATION
Muscles canwithstand rigorousmechanical stress and, if damaged,
be repaired by the progeny of satellite cells (Figure 1). Satellite cells
are quiescent muscle progenitor cells that reside along the basal
lamina of the muscle ﬁber and proliferate only in response to
speciﬁc signals, for example muscle injury (Charge and Rudnicki,
2004). For continuous and sufﬁcient muscle regeneration, satellite
cells must be easily activated to proliferate but also should return
to quiescence to maintain their stem cell characteristics (Dhawan
and Rando, 2005).
The progeny of satellite progenitor cells are primary myoblasts.
These myoblasts proliferate to increase in number and upon
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FIGURE 1 | Muscle damage can be repaired by the progeny of satellite
cells.When muscle ﬁbers need to be replaced, signals are sent to
otherwise quiescent satellite cells, which activates their proliferation and
generates proliferating myoblasts. Myoblasts later differentiate and fuse to
form myotubes. Myotubes cluster into myoﬁbers, the structures that
muscle cells consist of.
activation differentiate and fuse to form myotubes. These
myotubes then cluster into myoﬁbers which again cluster to form
muscle cells or myocytes. This program must be tightly regulated
to ensure that muscle is replenished as necessary and that satellite
cells are not lost in an untimely manner (Buckingham, 2006).
In order for a cell to be a myocyte it must express speciﬁc tran-
scription factors, including Mef2, MyoD, and myogenin among
others (Sabourin and Rudnicki, 2000). Before myoblasts express
these factors they are in a proliferative state that requires repression
of terminal differentiation genes and cell cycle inhibitors. In order
for differentiation of myoblasts to occur, proliferation must halt.
This requires the coordinated agreement of cell cycle inhibition
and initiation of muscle speciﬁc gene expression.
In dystrophic patients, Dys insufﬁciency causes the muscle sar-
colemma to become fragile leading to damage that cannot be easily
repaired due to inadequate response of satellite cells. This results in
chronic inﬂammation of muscle tissue by penetration of immune
cells and eventually leads to the replacement of myoﬁbers with
adipose and ﬁbrotic tissue (Porter et al., 2002).
Age-dependent muscle degeneration in MD patients is associ-
ated with defects in multiple processes that occur in different cell
types such as activationof satellite cell proliferation,progenitor cell
maintenance, myoblast differentiation, muscle cell homeostasis,
immune cell recruitment, etc. These processes are also required
during normalmuscle development and growth and the transcrip-
tional circuitry and signaling pathways controlling these events
have been extensively studied using many model organisms. In
this review we will discuss how recent studies have also revealed a
new level of regulation of muscle gene expression that is mediated
by miRNAs. Since miRNAs have great potential for therapeutics,
understanding their basic biology and speciﬁc functions in healthy
and diseased muscle tissue is of great importance.
THE Dys–Syn–nNOS PATHWAY AND miRNA LEVELS ARE
RECIPROCALLY REGULATED
The DGC through the Dys–Syn–nNOS pathway regulates the
expression of miRNAs required for muscle tissue maintenance
and regeneration (Cacchiarelli et al., 2010; Figure 2). Indeed,
it has been found that mRNA levels are altered in the human
DMD pathology, which correlates with mis-expressed miRNAs
(Eisenberg et al., 2007). Speciﬁcally nNOS signaling controls mod-
iﬁcation of HDAC2, which in normal situations prevents binding
to promoter regions that would lead to transcriptional activation.
When Dys is absent this signaling is disturbed,which also results in
miRNA dysregulation (Figure 3). Interestingly it was found that
most of the mis-expressed miRNAs found in DMD patients are
returned to normal expression levels when HDACs were inhib-
ited by restoring NO signaling (Cacchiarelli et al., 2010). This is
in accord with a previous study that showed that class I HDAC
inhibitors and NO-inhibited HDACs effectively ameliorate MD in
mouse models (Colussi et al., 2008).
Not only does the DGC play a role in miRNA regulation, but it
is also regulated via miRNAs. For example, miR-222 regulates the
Dys–Syn–nNOS pathway possibly by targeting the 3′-UTR of β1-
Syntrophin (De Arcangelis et al., 2010). Since Syntrophins bind
to Dys and act as a scaffold for nNOS, miR-222 could control
the timing of NO signaling during differentiation. miR-222 has
the same seed sequence as miR-221, both are controlled by the
Ras–MAPK pathway and are downregulated upon differentiation
of myoblasts (Cardinali et al., 2009). Additionally, miR-221 and
miR-222 promote cell cycle progression by down-regulating the
cyclin-dependent kinase inhibitors p27 (Cdkn1b/Kip1) and p57
(Cdkn1c/Kip2) that are essential for the maintenance of the pro-
liferative state (le Sage et al., 2007; Medina et al., 2008). Since
both miR-221 and miR-222 are signiﬁcantly upregulated in MDs
(Eisenberg et al., 2007; Greco et al., 2009; De Arcangelis et al.,
2010), the cell cycle kinetics of muscle progenitor cells could also
be affected.
Another miRNA that is known to regulate muscle terminal dif-
ferentiation genes is miR-31, which directly targets the 3′-UTR
or Dys consequently inactivating the Dys–Syn–nNOS pathway
(Cacchiarelli et al., 2011). In normal muscle, miR-31 activity is
detected in early myoblasts to suppress precocious expression of
late differentiation markers, while in dystrophic muscles miR-31
levels are elevated probably due to activation of the regenerative
program in differentiating satellite cells and myoblasts. Increased
miR-31 levels in these cells subsequently reduce the amount of
Dys, the lack of which correlateswith a differentiation delay (Greco
et al., 2009; Cacchiarelli et al., 2011). Importantly, in dystrophic
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FIGURE 2 |The Dys–Syn–nNOS pathway and miRNAs coordinate the
muscle differentiation program. Dys–Syn–nNOS signaling regulates the
epigenetic proﬁle of muscle cells via nitrosylation of HDAC2 that inﬂuences
gene expression by altering the acetylation status of histones. miR-221 and
miR-222 share the same seed sequence and both target cell cycle inhibitors,
p27 and p57. miR-222 also targets β1-Syn implying an impact on nNOS
signaling. miR-31 temporally targets terminal differentiation genes including
Dys. miR-1 and miR-133 are transcriptionally controlled by the nitrosylation
state of HDAC2, which is regulated by nNOS. miR-133 targets SRF during
proliferation, which in a self regulatory manner promotes expression of
miR-133. miR-1 targets G6PD and HDAC4 during differentiation, and since
HDAC4 regulates the transcription of muscle differentiation genes,
Dys–Syn–nNOS signaling indirectly promotes differentiation. In a
self-promoting regulatory loop, the expression of muscle differentiation genes
results in miR-1 expression. miR-29 is also transcriptionally controlled by the
nitrosylation state of HDAC2. Additional regulation of miR-29 comes from
YY1, a member of NF-κB signaling. The skeletal muscle speciﬁc miRNA,
miR-206 is also upregulated by muscle gene expression and aids in cell cycle
inhibition by targeting DNA Pola1 and Pax7. Utrophin is another target of
miR-206 providing another link between it and the DGC.
conditions, when Dys synthesis is rescued through exon skip-
ping, inhibition of miR-31 signiﬁcantly improved Dys production
(Cacchiarelli et al., 2011). As a result, downregulation of miR-31
most likely promotes generation of NO via Dys–Syn–nNOS sig-
naling and subsequent HDAC2 nitrosylation. Once nitrosylated,
HDAC2 no longer inhibits expression of select miRNAs (Cac-
chiarelli et al., 2010), for examplemuscle speciﬁcmiR-1 thatmarks
differentiating myoblasts (Chen et al., 2006).
miRNAs BALANCE THE EPIGENETIC NETWORK OF
DYSTROPHIC MUSCLE
miR-1 is evolutionarily conserved from invertebrates to vertebrates
and via targeting another histone deacetylase,HDAC4 (Chen et al.,
2006) it canmodulate epigenetic proﬁles of muscle genes.Multiple
HDAC4 transcriptionally regulated genes promote muscle differ-
entiation, including Mef2 (Lu et al., 2000; McKinsey et al., 2000;
Chen et al., 2006). Insights from research in Drosophila showed
that miR-1 is necessary for post-mitotic growth but not establish-
ment of muscles (Sokol and Ambros, 2005). miR-1 expression is
regulated initially by Twist, a mesoderm fate determining tran-
scription factor, then in later stages by Mef2 (Sokol and Ambros,
2005), a central regulator of myogenesis. This puts miR-1 in a
positive feedback loop where its expression is initiated and pro-
moted by the muscle differentiation program (myogenic factors
and Dys–Syn–nNOS signaling) and then, miR-1 acts to reassure
terminal differentiation through downregulation of HDAC4, a
repressor of myogenic genes.
In mdx mouse and human DMD patients, when Dys is absent
and NO signaling is perturbed, miR-1 is downregulated in dif-
ferentiating myoblasts (McCarthy and Esser, 2007; Greco et al.,
2009; Cacchiarelli et al., 2010). Myoﬁbers generated under such
conditions are not robust and can be lost as part of the disease
pathology. Transcriptomic analysis carried out on the dystrophic
mouse revealed an altered gene expression proﬁle that might affect
proper myoﬁber differentiation (Ghahramani Seno et al., 2010).
Additionally, miR-1 targets Glucose-6-phosphate dehydrogenase
(G6PD) that controls oxidative stress by maintaining levels of oxi-
dized and reduced glutathione, a major antioxidant (Cacchiarelli
et al., 2010). Since dystrophic muscle is sensitive to different
stresses and has altered levels of reactive oxygen/nitrogen species
(Martins et al., 2008; Shkryl et al., 2009; Kucherenko et al., 2011;
Marrone et al., 2011), ﬁnding new ways to protect against oxida-
tive stress is of a great signiﬁcance. Importantly, miRNAs have
been shown in many organisms to be involved in stress response
(Biggar and Storey, 2011; Dorn, 2011).
Once muscle differentiation genes start to be expressed they
in turn can regulate expression of miRNAs. miR-1 and miR-133
are transcribed together from a single primary transcript (Chen
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FIGURE 3 | In dystrophic muscle the epigenetic network of muscle
differentiation is disrupted.When Dys is absent, Dys–Syn–nNOS
signaling is disrupted inhibiting nitrosylation of HDAC2. Consequently,
levels of miR-133/miR-1 and miR-29, all of which are repressed by
non-nitrosylated HDAC2, are down. The regulatory roles of miR-133/miR-1
are disturbed leading to inhibition of muscle differentiation gene
expression and an increase in oxidative cellular stress. Muscle tissue
generated under imbalanced conditions will contribute to the procession
of adipogenesis. The decrease in miR-29 levels correlates with an increase
in the amount of Collagen and Elastin that are indicative of fat and ﬁbrotic
tissue. Due to reasons that are not quite clear at this time, levels of
miR-206 and miR-31 are increased altering the equilibrium between the
proliferation and differentiation states. miRNAs circled in green are
upregulated and miRNAs circled in red are down regulated, bold letters
indicate upregulated protein levels, gray circles with diagonal lines and
gray lines indicate deﬁciencies.
et al., 2006); however, they perform antagonistic functions in
muscle regeneration. For instance, during proliferation miR-133
is upregulated to target serum response factor (SRF), which is
important duringmuscle differentiation (Gauthier-Rouviere et al.,
1996; Wang et al., 2002; Li et al., 2005; Chen et al., 2006). In
a negative feedforward loop SRF also promotes the expression
of miR-133 (Chen et al., 2006). In addition, induction of miR-
1/133 and miR-206 (discussed later) transcription is regulated by
other factors that drive myogenesis including MyoD and Mef2
(Kim et al., 2006; Rao et al., 2006; Rosenberg et al., 2006); how-
ever, the amount of miR-133 decreases during differentiation.
It is interesting that miR-133, an enhancer of proliferation, and
miR-1, an enhancer of differentiation, are involved in temporally
separated developmental processes but are transcribed together.
This supports the idea that there is posttranscriptional regula-
tion of these miRNAs by an as yet unknown mechanism. For
example, primary miRNA (pri-miRNA) could be processed by
auxiliary factors. It has been shown that an RNA processing pro-
tein (hnRNP A1) promotes production of one miRNA over the
other members of the cluster via binding to the terminal loop of
the pri-miRNA (Michlewski et al., 2008). Despite initial beliefs
that the terminal loops of pri-miRNAs are unimportant, a large
number of pri-miRNAs including transcripts of miR-1 and miR-
133 have conserved terminal loops, which suggests that miR-1/133
in muscle could be regulated posttranscriptionally. Nonetheless,
similar to miR-1, in dystrophic muscle miR-133 is downregulated
(McCarthy and Esser, 2007; Cacchiarelli et al., 2010) supporting
that proliferation and differentiation of satellite cells are disrupted
in DMD patients.
When early muscle transcription factors start to be expressed
they promote expression of several miRNAs, which in turn ﬁne-
tune signals required to reprogram cells to differentiate and fuse
into myotubes. Skeletal muscle speciﬁc miR-206 is upregulated in
activated myoblasts to aid differentiation and halt proliferation
via cell cycle arrest (Kim et al., 2006). This is accomplished by
inhibiting DNA synthesis by targeting Pola1, a DNA polymerase
(Kim et al., 2006). Additionally, miR-206 targets the satellite cell
self renewal factor, Pax7 (Cacchiarelli et al., 2010), and the muscle
differentiation inhibitor HDAC4 (Williams et al., 2009). Though
miR-206 can be positively regulated by muscle differentiation
genes similar to miR-1/133, in dystrophic muscle the levels of this
miRNA are higher than normal (McCarthy et al., 2007;Yuasa et al.,
2008; Greco et al., 2009; Cacchiarelli et al., 2010). Interestingly,
Utrophin, a Dys homolog, which due to a compensatory mecha-
nism is upregulated in themdx mouse, is another target of miR-206
(Rosenberg et al., 2006). However, increased levels of miR-206 as
a part of the DMD pathology do not agree with increased levels of
Utrophin (McCarthy et al., 2007), suggesting that compensatory
mechanisms act independent from miR-206. Unlike miR-1/133,
miR-206 is not repressed by HDAC2, but by HDAC1 (Cacchiarelli
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et al., 2010). This indicates that miR-206 is not regulated by the
Dys–Syn–nNOS pathway; however, miR-206 contributes to the
imbalance of the regeneration program in dystrophic muscle.
miRNAs REGULATE TISSUE REPLACEMENT IN
COMPROMISED DYSTROPHIC MUSCLE
Even though different types of MDs have speciﬁc mechanisms of
muscle degeneration, inﬂammation is a hallmark symptomof dys-
trophic muscle. Accordingly, an increase in miR-222 and miR-223
levels in dystrophic muscle is believed to be due to inﬂamma-
tion (Eisenberg et al., 2007; Greco et al., 2009). Inﬂammation is
associated with fat and ﬁbrotic replacement of muscle ﬁbers and
degeneration (Porter et al., 2002). To elucidate the differences seen
in different types of muscular disorders a comprehensive study
was carried out in which muscle specimens were analyzed repre-
senting 10 different human conditions (Eisenberg et al., 2007).
What was learned from this study is that (1) there is a large
amount of variation in miRNA levels in disease states, (2) there
are shared misregulated miRNAs across muscular disorders (miR-
146b and miR-miR-221) and (3) only a small number of miRNAs
are unique to an individual disorder such as DMD (miR-95, miR-
30d,miR-486,miR-331,miR-193b,miR-30a_5p,miR-30e_5p, and
miR-26a).
Previously it was thought that improper fate determination of
satellite cell progeny generated extra ﬁbrotic tissue in dystrophic
muscle (Shefer et al., 2004; Brack et al., 2007). Fibrosis therefore
ought to occur at the expense of muscle regeneration. However,
recently it has been shown that in addition to satellite muscle
progenitor cells, there are also mesenchymal progenitor cells liv-
ing among myoﬁbers that give rise to adipocytes and ﬁbroblasts
which generate fat/ﬁbrotic tissue (Joe et al., 2010; Uezumi et al.,
2010). These cells have been termed ﬁbro/adipogenic progeni-
tors (Natarajan et al., 2010). What is amazing about these cells
is that they are activated during muscle regeneration similar to
satellite cells, but in a non-autonomous manner receive signals
from the surrounding muscle environment. If muscle regenera-
tion is producing normal healthy muscle ﬁbers then adipogenesis
is inhibited. However, if muscle regeneration is compromised then
adipogenesis proceeds and ﬁbrotic tissue will arise in the inter-
stitial space between myoﬁbers (Figure 4). Certain proteins are
indicative of ﬁbrotic tissue such as collagen and elastin. Recently
it has been shown that their mRNAs are targeted by the miR-29
family, which helps to modify ECM organization (van Rooij et al.,
2008). miR-29 is an enhancer of differentiation and is repressed in
myoblasts by Yin Yang 1 (YY1), a protein that is positively regu-
lated by NF-κB and is a member of the Polycomb group that acts
as a transcriptional silencer (Wang et al., 2008). During myoge-
nesis expression of miR-29 is upregulated by SRF and Mef2, and
in a self regulatory manner, miR-29 suppresses YY1 and HDAC4
by targeting their 3′-UTRs (Wang et al., 2008; Li et al., 2009).
Interestingly, the expression of miR-29 is also controlled by the
Dys–Syn–nNOS pathway where, similar to miR-1, nitrosylation
of HDAC2 allows for its transcription (Cacchiarelli et al., 2010).
In mdx mouse and human DMD patients there is therefore an
expected decrease in miR-29 levels which promotes an increase in
ﬁbrotic tissue (Eisenberg et al., 2007;Greco et al., 2009;Cacchiarelli
et al., 2010).
FIGURE 4 | Myotube health regulates adipogenesis. If muscle is
regenerating normally then ﬁbro/adipogenic progenitor cells will receive a
non-cell autonomous signal from the muscle environment and die. The
signal from the degenerative muscle environment stimulates
ﬁbro/adipogenic progenitor cells to give rise to adipocites and ﬁbroblasts
that will differentiate into fat and ﬁbrotic tissue.
All of these ﬁndings lead to the conclusion that in dystrophic
muscle the alteration in miRNA levels is the result of an imbal-
anced regeneration program, where not only activation of satellite
cell proliferation but also myoblast differentiation are impaired
(Figure 3). The overall result is that damaged muscle ﬁbers do
not properly regenerate resulting in fat and ﬁbrotic tissue replace-
ment with accompanying inﬂammation. Each of these processes
is accompanied by misregulation of certain miRNAs that can be
considered in a multistep treatment of these fatal neuromuscular
disorders.
NEW OPTIONS FOR miRNAs IN MUSCULAR DYSTROPHY
THERAPIES
As discussed above, miRNA dysregulation contributes to a variety
of MD pathologies and the miRNA regulatory network is dis-
turbed in dystrophic muscle. In order to return the diseased tissue
to normal mode, multiple processes have to be adjusted, and miR-
NAs are important functional units controlling different aspects
of muscle regeneration and maintenance. In addition, miRNAs
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have been shown to be perfect players in ﬁne-tuning different
developmental processes: stem cell division and maintenance, dif-
ferentiation, cell cycle control, etc (Shcherbata et al., 2006; Inui
et al., 2010). Therefore re-establishing the normal miRNA levels
may allow for improvement of misregulated protein synthesis. The
proteomic ﬁngerprint can be altered by variation of miRNA levels,
which can be achieved in a positive or a negative manner. miR-
NAs can be inhibited by in vivo silencing via use of chemically
modiﬁed antisense nucleotides locked nucleid acids (LNA; Kumar
et al., 1998), 2′-O-methyl-RNA oligonucleotides (2′-O-me-RNA;
Matera and Ward, 1993), microRNA sponges (Ebert et al., 2007),
or cholesterol conjugated RNA analogs (antagomirs; Krutzfeldt
et al., 2005). Inversely miRNA levels can be increased by in vivo
injection or viral delivery resulting in reduced expression of upreg-
ulated disease genes (Fasanaro et al., 2010; Pfeifer and Lehmann,
2010).
An exemplary result of miRNA targeting in DMD therapy
comes from Cacchiarelli et al. (2011). In mdx mice symptoms of
muscle degeneration can be reversed by the introduction of viral
vectors that allow for transcriptional exon skipping that removes
a non-sense mutation in the Dys gene. However, these therapies
have not been able to restore full muscle function due to low Dys
levels. Dys is a target for miR-31 and any replacement of Dys via
genetic manipulation could potentially be inhibited by the pres-
ence of this miRNA. The authors were able to signiﬁcantly increase
Dys levels in exon skipping treated DMD myoblasts by downregu-
lation of miR-31 using a miR-31 sponge and an anti-miR-31 LNA
oligonucleotide. These results set a precedent for the use of miR-
NAs as therapeutic targets to alleviate muscular dystrophy. It is
unknown at this time if there are other mRNA targets of miR-31,
alteration of which would give rise to deleterious side effects of
this treatment.
Fibrotic degeneration, which is characteristic in mdx mice,
was also successfully decreased by increasing miR-29 levels (Cac-
chiarelli et al., 2010). Electroporation of mdx muscles with miR-29
had a therapeutic effect resulting in signiﬁcant reduction of col-
lagen deposition and an increase in both collagen and elastin
mRNAs. These data prove that miRNAs are crucial regulators
of the ECM that can possibly regulate the signals sent from the
muscle environment to ﬁbro/adipogenic progenitors, and target-
ing/promoting such miRNAs could inhibit ﬁbrosis allowing for
more successful muscle regeneration.
Though it seems obvious from the discussion presented thus
far that Dys–Syn–nNOS signaling plays a key role in balancing
the epigenetic network of muscle regeneration, it must be consid-
ered that therapies restoring NO signaling alone may not be fully
curative. Patients with the milder BMD in some cases are missing
the domain of Dys essential for Dys–Syn–nNOS signaling (Wells
et al., 2003; Lai et al., 2009). Since these patients do not succumb
to their illness, the malfunction of nNOS signaling is still com-
patible with life. Key muscle regenerative miRNAs regulated by
nNOS signaling are probable therapeutic targets; however other
isolated miRNAs should be given attention for disease treatment
too. Screening for misregulated miRNAs has been done by several
groups in dystrophic animal models and DMD patients which
allowed to compile a comprehensive list of differentially regulated
miRNAs that can be clustered intro three functional categories:
regeneration, degeneration, and inﬂammation (Eisenberg et al.,
2007; Greco et al., 2009).
RegenerativemiRNAs are upregulatedduring embryonic devel-
opment and post ischemic regeneration (Greco et al., 2009; Suh
and Blelloch, 2011), supporting their role in proliferation and
differentiation of muscle cell progenitors. This indicates that func-
tional tissue replacement is based on satellite cell populations, and
for miRNA-based therapies to be effective progenitor cell main-
tenance and division should be taken into consideration. Muscle
satellite cells are quiescent until they become proliferative upon
response to muscle damage or heavy use. It will be of interest to
determine what role miRNAs have in the initial activation of satel-
lite cells, since it has been shown that miRNA signatures differ
from self-renewing to quiescent stem cells and from proliferative
to differentiating progenitor cells (Arnold et al., 2011).
Initially it was believed that the role of the DGC was to simply
provide structural support at costameres and without this sup-
port the muscle cell would tear and waste away. However, that is
obviously not the only avenue with which disease progresses. The
DGC is right in the middle of the muscle differentiation program,
since without the Dys–Syn–nNos pathway muscle maintenance
and regeneration is disrupted. This means that formed myotubes
are compromised and contribute to tissue replacement by fat and
ﬁbrosis. The plethora of miRNAs implicated in the DMD pathol-
ogy present a substantial and complex level of regulation that
opens diverse avenues for future research and therapies.
ACKNOWLEDGMENTS
We would like to thank Gerd Vorbrüggen and all members of
Shcherbata Lab for comments on the manuscript and Max Planck
Society for ﬁnancial support.
REFERENCES
Arnold,C. P.,Tan,R.,Zhou,B.,Yue,S. B.,
Schaffert, S., Biggs, J. R., Doyonnas,
R., Lo, M. C., Perry, J. M., Renault,
V. M., Sacco, A., Somervaille, T.,Via-
tour, P., Brunet, A., Cleary, M. L., Li,
L., Sage, J., Zhang, D. E., Blau, H. M.,
Chen, C., and Chen, C. Z. (2011).
MicroRNA programs in normal and
aberrant stem and progenitor cells.
Genome Res. 21, 798–810.
Biggar, K. K., and Storey, K. B. (2011).
The emerging roles of microRNAs
in the molecular responses of meta-
bolic rate depression. J. Mol. Cell
Biol. 3, 167–175.
Brack, A. S., Conboy, M. J., Roy, S., Lee,
M., Kuo, C. J., Keller, C., and Rando,
T.A. (2007). IncreasedWnt signaling
during aging alters muscle stem cell
fate and increases ﬁbrosis. Science
317, 807–810.
Brenman, J. E., Chao, D. S., Xia,
H., Aldape, K., and Bredt, D. S.
(1995). Nitric oxide synthase com-
plexed with dystrophin and absent
from skeletal muscle sarcolemma in
Duchenne muscular dystrophy. Cell
82, 743–752.
Buckingham, M. (2006). Myogenic
progenitor cells and skeletal myo-
genesis in vertebrates. Curr. Opin.
Genet. Dev. 16, 525–532.
Cacchiarelli, D., Incitti, T., Martone,
J., Cesana, M., Cazzella, V., San-
tini, T., Sthandier, O., and Boz-
zoni, I. (2011). miR-31 modulates
dystrophin expression: new impli-
cations for Duchenne muscular
dystrophy therapy. EMBO Rep. 12,
136–141.
Cacchiarelli, D., Martone, J., Girardi,
E., Cesana, M., Incitti, T., Mor-
lando, M., Nicoletti, C., Santini, T.,
Sthandier, O., Barberi, L., Auric-
chio, A., Musaro, A., and Bozzoni,
I. (2010). MicroRNAs involved in
molecular circuitries relevant for
the Duchenne muscular dystro-
phy pathogenesis are controlled by
the dystrophin/nNOS pathway. Cell
Metab. 12, 341–351.
Frontiers in Genetics | Non-Coding RNA September 2011 | Volume 2 | Article 64 | 6
Marrone and Shcherbata Dystrophin and microRNAs balance myoregeneration
Campbell, K. P. (1995). Three muscu-
lar dystrophies: loss of cytoskeleton-
extracellular matrix linkage. Cell 80,
675–679.
Cardinali, B., Castellani, L., Fasanaro, P.,
Basso, A., Alema, S., Martelli, F., and
Falcone, G. (2009). Microrna-221
and microrna-222 modulate differ-
entiation and maturation of skeletal
muscle cells. PLoS ONE 4, e7607.
doi:10.1371/journal.pone.0007607
Charge, S. B., and Rudnicki, M. A.
(2004). Cellular andmolecular regu-
lation of muscle regeneration. Phys-
iol. Rev. 84, 209–238.
Chen, J. F., Mandel, E. M., Thomson, J.
M., Wu, Q., Callis, T. E., Hammond,
S. M., Conlon, F. L., and Wang, D.
Z. (2006). The role of microRNA-1
and microRNA-133 in skeletal mus-
cle proliferation and differentiation.
Nat. Genet. 38, 228–233.
Cohn,R. D., and Campbell, K. P. (2000).
Molecular basis of muscular dystro-
phies. Muscle Nerve 23, 1456–1471.
Colussi, C., Mozzetta, C., Gurtner, A.,
Illi, B., Rosati, J., Straino, S., Ragone,
G., Pescatori, M., Zaccagnini, G.,
Antonini,A.,Minetti,G.,Martelli, F.,
Piaggio, G., Gallinari, P., Steinkuh-
ler, C., Clementi, E., Dell’aversana,
C., Altucci, L., Mai, A., Capogrossi,
M. C., Puri, P. L., and Gaetano,
C. (2008). HDAC2 blockade by
nitric oxide and histone deacetylase
inhibitors reveals a common tar-
get in duchenne muscular dystro-
phy treatment. Proc. Natl. Acad. Sci.
U.S.A. 105, 19183–19187.
Constantin, B., Sebille, S., and Cog-
nard, C. (2006). New insights in the
regulation of calcium transfers by
muscle dystrophin-based cytoskele-
ton: implications in DMD. J. Muscle
Res. Cell Motil. 27, 375–386.
De Arcangelis, V., Serra, F., Cogoni, C.,
Vivarelli, E., Monaco, L., and Naro,
F. (2010). Beta1-syntrophin modu-
lationbymiR-222 inmdxmice.PLoS
ONE 5, 12098. doi:10.1371/jour-
nal.pone.0012098
Dhawan, J., and Rando, T. A. (2005).
Stem cells in postnatal myogene-
sis: molecular mechanisms of satel-
lite cell quiescence, activation and
replenishment. Trends Cell Biol. 15,
666–673.
Dorn, G. W. II. (2011). MicroRNAs
in cardiac disease. Transl. Res. 157,
226–235.
Durbeej, M., and Campbell, K. P.
(2002). Muscular dystrophies
involving the dystrophin-
glycoprotein complex: an overview
of current mouse models. Curr.
Opin. Genet. Dev. 12, 349–361.
Ebert, M. S., Neilson, J. R., and Sharp, P.
A. (2007). MicroRNA sponges: com-
petitive inhibitors of small RNAs in
mammalian cells. Nat. Methods 4,
721–726.
Eisenberg, I., Eran, A., Nishino, I., Mog-
gio, M., Lamperti, C., Amato, A. A.,
Lidov, H. G., Kang, P. B., North, K.
N., Mitrani-Rosenbaum, S., Flani-
gan, K. M., Neely, L. A., Whit-
ney, D., Beggs, A. H., Kohane, I. S.,
and Kunkel, L. M. (2007). Distinc-
tive patterns of microRNA expres-
sion in primary muscular disorders.
Proc. Natl. Acad. Sci. U.S.A. 104,
17016–17021.
Ervasti, J. M., and Sonnemann, K.
J. (2008). Biology of the striated
muscle dystrophin-glycoprotein
complex. Int. Rev. Cytol. 265,
191–225.
Fasanaro, P., Greco, S., Ivan, M.,
Capogrossi, M. C., and Martelli, F.
(2010). microRNA: emerging thera-
peutic targets in acute ischemic dis-
eases. Pharmacol. Ther. 125, 92–104.
Gauthier-Rouviere, C., Vandromme,
M., Tuil, D., Lautredou, N., Morris,
M., Soulez, M., Kahn, A., Fernandez,
A., and Lamb, N. (1996). Expression
and activity of serum response fac-
tor is required for expression of the
muscle-determining factor MyoD in
both dividing and differentiating
mouse C2C12 myoblasts. Mol. Biol.
Cell 7, 719–729.
Ghahramani Seno, M. M., Trollet, C.,
Athanasopoulos, T., Graham, I. R.,
Hu,P., andDickson,G. (2010). Tran-
scriptomic analysis of dystrophin
RNAi knockdown reveals a central
role for dystrophin in muscle dif-
ferentiation and contractile appara-
tus organization. BMC Genomics 11,
345. doi:10.1186/1471-2164-11-345
Greco, S., De Simone, M., Colussi, C.,
Zaccagnini, G., Fasanaro, P., Pesca-
tori, M., Cardani, R., Perbellini,
R., Isaia, E., Sale, P., Meola, G.,
Capogrossi, M. C., Gaetano, C., and
Martelli, F. (2009). Common micro-
RNA signature in skeletal muscle
damage and regeneration induced
by Duchenne muscular dystrophy
and acute ischemia. FASEB J. 23,
3335–3346.
Hoffman, E. P., Brown, R. H. Jr., and
Kunkel, L. M. (1987). Dystrophin:
the protein product of theDuchenne
muscular dystrophy locus. Cell 51,
919–928.
Inui, M., Martello, G., and Piccolo, S.
(2010). MicroRNA control of sig-
nal transduction. Nat. Rev. Mol. Cell
Biol. 11, 252–263.
Joe, A. W., Yi, L., Natarajan, A., Le
Grand, F., So, L., Wang, J., Rud-
nicki, M. A., and Rossi, F. M.
(2010). Muscle injury activates res-
ident ﬁbro/adipogenic progenitors
that facilitate myogenesis. Nat. Cell
Biol. 12, 153–163.
Kim, H. K., Lee, Y. S., Sivaprasad,
U., Malhotra, A., and Dutta, A.
(2006). Muscle-speciﬁc microRNA
miR-206 promotes muscle dif-
ferentiation. J. Cell Biol. 174,
677–687.
Krutzfeldt, J., Rajewsky, N., Braich, R.,
Rajeev, K. G., Tuschl, T., Manoha-
ran, M., and Stoffel, M. (2005).
Silencing of microRNAs in vivo with
“antagomirs.” Nature 438, 685–689.
Kucherenko, M. M., Marrone, A. K.,
Rishko, V. M., Magliarelli Hde,
F., and Shcherbata, H. R. (2011).
Stress and muscular dystrophy:
a genetic screen for dystrogly-
can and dystrophin interactors in
Drosophila identiﬁes cellular stress
response components. Dev. Biol.
352, 228–242.
Kumar, R., Singh, S. K., Koshkin, A.
A., Rajwanshi, V. K., Meldgaard, M.,
and Wengel, J. (1998). The ﬁrst
analogues of LNA (locked nucleic
acids): phosphorothioate-LNA and
2(′-thio-LNA. Bioorg. Med. Chem.
Lett. 8, 2219–2222.
Kunkel, L. M., Hejtmancik, J. F., Caskey,
C. T., Speer, A., Monaco, A. P., Mid-
dlesworth, W., Colletti, C. A., Ber-
telson, C., Muller, U., Bresnan, M.,
Shapiro, F., Tantravahi, U., Speer,
J., Latt, S. A., Bartlett, R., Pericak-
Vance, M. A., Roses, A. D., Thomp-
son,M. W., Ray, P. N.,Worton, R. G.,
Fischbeck,K.H.,Gallano,P.,Coulon,
M., Duros, C., Boue, J., Junien, C.,
Chelly, J., Hamard, G., Jeanpierre,
M., Lambert, M., Kaplan, J. C.,
Emery, A., Dorkins, H., Mcglade, S.,
Davies, K. E., Boehm,C.,Arveiler, B.,
Lemaire, C., Morgan, G. J., Denton,
M. J.,Amos, J., Bobrow,M., Benham,
F., Boswinkel, E., Cole,C.,Dubowitz,
V.,Hart,K.,Hodgson,S., Johnson,L.,
Walker, A., Roncuzzi, L., Ferlini, A.,
Nobile, C., Romeo, G.,Wilcox, D. E.,
Affara,N.A., Ferguson-Smith,M.A.,
Lindolf,M.,Kaariainen,H.,DeLa,C.
A., Ionasescu, V., Searby, C., Ionas-
escu, R., Bakker, E., Van Ommen,
G. J., Pearson, P. L., Greenberg, C.
R., Hamerton, J. L., Wrogemann,
K., Doherty, R. A., Polakowska, R.,
Hyser, C., Quirk, S., Thomas, N.,
Harper, J. F., Darras, B. T., and
Francke, U. (1986). Analysis of dele-
tions in DNA from patients with
Becker andDuchennemuscular dys-
trophy. Nature 322, 73–77.
Lai, Y., Thomas, G. D., Yue, Y., Yang, H.
T., Li, D., Long, C., Judge, L., Bostick,
B., Chamberlain, J. S., Terjung, R. L.,
and Duan, D. (2009). Dystrophins
carrying spectrin-like repeats 16 and
17 anchor nNOS to the sarcolemma
and enhance exercise performance
in a mouse model of muscular dys-
trophy. J. Clin. Invest. 119, 624–635.
le Sage, C., Nagel, R., Egan, D. A.,
Schrier, M., Mesman, E., Mangi-
ola, A., Anile, C., Maira, G., Mer-
catelli, N., Ciafre, S. A., Farace, M.
G., andAgami,R. (2007). Regulation
of the p27(Kip1) tumor suppressor
by miR-221 and miR-222 promotes
cancer cell proliferation.EMBOJ.26,
3699–3708.
Li, S., Czubryt, M. P., Mcanally,
J., Bassel-Duby, R., Richardson, J.
A., Wiebel, F. F., Nordheim, A.,
and Olson, E. N. (2005). Require-
ment for serum response fac-
tor for skeletal muscle growth
and maturation revealed by tissue-
speciﬁc gene deletion in mice.
Proc. Natl. Acad. Sci. U.S.A. 102,
1082–1087.
Li, Z., Hassan, M. Q., Jafferji, M.,
Aqeilan, R. I., Garzon, R., Croce,
C. M., Van Wijnen, A. J., Stein,
J. L., Stein, G. S., and Lian, J. B.
(2009). Biological functions of miR-
29b contribute to positive regulation
of osteoblast differentiation. J. Biol.
Chem. 284, 15676–15684.
Lu, J., Mckinsey, T. A., Zhang, C. L., and
Olson, E. N. (2000). Regulation of
skeletal myogenesis by association of
the MEF2 transcription factor with
class II histone deacetylases. Mol.
Cell 6, 233–244.
Marrone, A. K., Kucherenko, M. M.,
Wiek, R., Gopfert, M. C., and
Shcherbata, H. R. (2011). Hyper-
thermic seizures and aberrant cellu-
lar homeostasis in Drosophila dys-
trophic muscles. Sci. Rep. 1. doi:
10.1038/srep00047.
Martins, A. S., Shkryl, V. M., Nowycky,
M. C., and Shirokova, N. (2008).
Reactive oxygen species contribute
to Ca2+ signals produced by
osmotic stress in mouse skeletal
muscle ﬁbres. J. Physiol. (Lond.) 586,
197–210.
Matera, A. G., and Ward, D. C. (1993).
Nucleoplasmic organizationof small
nuclear ribonucleoproteins in cul-
tured human cells. J. Cell Biol. 121,
715–727.
McCarthy, J. J., and Esser, K. A. (2007).
MicroRNA-1 and microRNA-133a
expression are decreased during
skeletal muscle hypertrophy. J. Appl.
Physiol. 102, 306–313.
McCarthy, J. J., Esser, K. A., and
Andrade, F. H. (2007). MicroRNA-
206 is overexpressed in the
diaphragm but not the hindlimb
muscle of mdxmouse.Am. J. Physiol.
Cell Physiol. 293, C451–C457.
McKinsey, T. A., Zhang, C. L., Lu, J.,
and Olson, E. N. (2000). Signal-
dependent nuclear export of a
histone deacetylase regulates mus-
cle differentiation. Nature 408,
106–111.
www.frontiersin.org September 2011 | Volume 2 | Article 64 | 7
Marrone and Shcherbata Dystrophin and microRNAs balance myoregeneration
Medina, R., Zaidi, S. K., Liu, C. G.,
Stein, J. L., Van Wijnen, A. J.,
Croce, C. M., and Stein, G. S.
(2008). MicroRNAs 221 and 222
bypass quiescence and compro-
mise cell survival. Cancer Res. 68,
2773–2780.
Michlewski, G., Guil, S., Semple, C. A.,
and Caceres, J. F. (2008). Posttran-
scriptional regulation of miRNAs
harboring conserved terminal loops.
Mol. Cell 32, 383–393.
Moore, C. J., and Winder, S. J. (2010).
Dystroglycan versatility in cell adhe-
sion: a tale of multiple motifs. Cell
Commun. Signal. 8, 3.
Natarajan, A., Lemos, D. R., and Rossi,
F.M. (2010). Fibro/adipogenic prog-
enitors: a double-edged sword in
skeletal muscle regeneration. Cell
Cycle 9, 2045–2046.
Pfeifer, A., and Lehmann, H. (2010).
Pharmacological potential of
RNAi – focus onmiRNA.Pharmacol.
Ther. 126, 217–227.
Porter, J. D., Khanna, S., Kaminski, H. J.,
Rao, J. S.,Merriam,A.P.,Richmonds,
C. R., Leahy, P., Li, J., Guo, W., and
Andrade, F. H. (2002). A chronic
inﬂammatory response dominates
the skeletal muscle molecular
signature in dystrophin-deﬁcient
mdx mice. Hum. Mol. Genet. 11,
263–272.
Puri, P. L., Iezzi, S., Stiegler, P., Chen,
T. T., Schiltz, R. L., Muscat, G. E.,
Giordano, A., Kedes, L., Wang, J.
Y., and Sartorelli, V. (2001). Class
I histone deacetylases sequentially
interact with MyoD and pRb dur-
ing skeletal myogenesis. Mol. Cell 8,
885–897.
Rao, P. K., Kumar, R. M., Farkhondeh,
M., Baskerville, S., and Lodish, H. F.
(2006). Myogenic factors that reg-
ulate expression of muscle-speciﬁc
microRNAs. Proc. Natl. Acad. Sci.
U.S.A. 103, 8721–8726.
Rosenberg, M. I., Georges, S. A.,
Asawachaicharn, A., Analau, E., and
Tapscott, S. J. (2006). MyoD inhibits
Fstl1 and Utrn expression by induc-
ing transcription of miR-206. J. Cell
Biol. 175, 77–85.
Sabourin, L. A., and Rudnicki, M. A.
(2000). The molecular regulation of
myogenesis. Clin. Genet. 57, 16–25.
Shcherbata, H. R., Hatﬁeld, S., Ward,
E. J., Reynolds, S., Fischer, K. A.,
and Ruohola-Baker, H. (2006). The
MicroRNA pathway plays a regula-
tory role in stem cell division. Cell
Cycle 5, 172–175.
Shefer, G., Wleklinski-Lee, M., and
Yablonka-Reuveni, Z. (2004). Skele-
tal muscle satellite cells can spon-
taneously enter an alternative mes-
enchymal pathway. J. Cell Sci. 117,
5393–5404.
Shkryl, V. M., Martins, A. S., Ullrich,
N. D., Nowycky, M. C., Niggli, E.,
andShirokova,N. (2009). Reciprocal
ampliﬁcation of ROS and Ca(2+)
signals in stressed mdx dystrophic
skeletal muscle ﬁbers. Pﬂugers Arch.
458, 915–928.
Sokol, N. S., and Ambros, V. (2005).
Mesodermally expressed Drosophila
microRNA-1 is regulated by twist
and is required in muscles dur-
ing larval growth. Genes Dev. 19,
2343–2354.
Suh, N., and Blelloch, R. (2011). Small
RNAs in early mammalian develop-
ment: from gametes to gastrulation.
Development 138, 1653–1661.
Uezumi, A., Fukada, S., Yamamoto, N.,
Takeda, S., and Tsuchida, K. (2010).
Mesenchymal progenitors distinct
from satellite cells contribute to
ectopic fat cell formation in skeletal
muscle. Nat. Cell Biol. 12, 143–152.
van Rooij, E., Liu, N., and Olson,
E. N. (2008). MicroRNAs ﬂex
their muscles. Trends Genet. 24,
159–166.
Vercherat, C., Chung, T. K., Yalcin, S.,
Gulbagci, N., Gopinadhan, S., Ghaf-
fari, S., and Taneja, R. (2009). Stra13
regulates oxidative stress mediated
skeletal muscle degeneration. Hum.
Mol. Genet. 18, 4304–4316.
Wallace, G. Q., and McNally, E.
M. (2009). Mechanisms of mus-
cle degeneration, regeneration, and
repair in the muscular dystrophies.
Annu. Rev. Physiol. 71, 37–57.
Wang, D., Passier, R., Liu, Z. P., Shin,
C. H., Wang, Z., Li, S., Suther-
land, L. B., Small, E., Krieg, P. A.,
and Olson, E. N. (2002). Regula-
tion of cardiac growth and develop-
ment by SRF and its cofactors. Cold
Spring Harb. Symp. Quant. Biol. 67,
97–105.
Wang, H., Garzon, R., Sun, H., Lad-
ner, K. J., Singh, R., Dahlman, J.,
Cheng, A., Hall, B. M., Qualman,
S. J., Chandler, D. S., Croce, C. M.,
and Guttridge, D. C. (2008). NF-
kappaB-YY1-miR-29 regulatory cir-
cuitry in skeletal myogenesis and
rhabdomyosarcoma. Cancer Cell 14,
369–381.
Wehling,M., Spencer,M. J., and Tidball,
J. G. (2001). A nitric oxide synthase
transgene ameliorates muscular dys-
trophy in mdx mice. J. Cell Biol. 155,
123–131.
Wells, K. E., Torelli, S., Lu, Q., Brown,
S. C., Partridge, T., Muntoni, F.,
and Wells, D. J. (2003). Relocaliza-
tion of neuronal nitric oxide syn-
thase (nNOS) as a marker for com-
plete restoration of the dystrophin
associated protein complex in skele-
tal muscle. Neuromuscul. Disord. 13,
21–31.
Williams, A. H., Valdez, G., Moresi, V.,
Qi, X., Mcanally, J., Elliott, J. L.,
Bassel-Duby, R., Sanes, J. R., and
Olson, E. N. (2009). MicroRNA-
206 delays ALS progression and pro-
motes regeneration of neuromuscu-
lar synapses in mice. Science 326,
1549–1554.
Yuasa, K., Hagiwara, Y., Ando, M.,
Nakamura, A., Takeda, S., and
Hijikata, T. (2008). MicroRNA-206
is highly expressed in newly formed
muscle ﬁbers: implications regard-
ing potential for muscle regener-
ation and maturation in muscu-
lar dystrophy. Cell Struct. Funct. 33,
163–169.
Conﬂict of Interest Statement: The
authors declare that the research was
conducted in the absence of any
commercial or ﬁnancial relationships
that could be construed as a potential
conﬂict of interest.
Received: 12 July 2011; paper pending
published: 29 July 2011; accepted: 26
August 2011; published online: 13 Sep-
tember 2011.
Citation: Marrone AK and Shcherbata
HR (2011) Dystrophin orchestrates
the epigenetic proﬁle of muscle cells
via miRNAs. Front. Gene. 2:64. doi:
10.3389/fgene.2011.00064
This article was submitted to Frontiers in
Non-CodingRNA, a specialty of Frontiers
in Genetics.
Copyright © 2011 Marrone and
Shcherbata. This is an open-access article
subject to a non-exclusive license between
the authors and Frontiers Media SA,
which permits use, distribution and
reproduction in other forums, provided
the original authors and source are
credited and other Frontiers conditions
are complied with.
Frontiers in Genetics | Non-Coding RNA September 2011 | Volume 2 | Article 64 | 8
